Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension

Pedro Marques da Silva, Uwe Haag, Julian F Guest, John E Brazier, Marco Soro, Pedro Marques da Silva, Uwe Haag, Julian F Guest, John E Brazier, Marco Soro

Abstract

Background: A post-hoc analysis was performed on the data from a 54 weeks phase III study (ClinicalTrials.gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ), using the MINICHAL and EQ-5D instruments.

Methods: Descriptive statistics were used to assess blood pressure and HRQoL scores over the study period. Analysis of covariance (ANCOVA) was used to identify those factors that could possibly have influenced HRQoL. Linear regression was used to assess the relationship between changes in blood pressure and HRQoL scores.

Results: Patients' baseline MINICHAL mood and somatic domains scores were 5.5 and 2.6. Over the study period HRQoL improved as both MINICHAL scores decreased by 31-33%. Patients' baseline EQ-5D index and VAS scores were 0.9 and 73.4 respectively, increasing by 6% and 12% over the study period. Patients' QALY gain over the 54 weeks study period was estimated to be 0.029 QALYs. The ANCOVA showed that changes in patients' HRQoL was likely to have been influenced by patients' achievement of blood pressure control, the amount of concomitant medication and patients' last used dosage strength of antihypertensive. Linear regression showed that blood pressure improvement may have been associated with improved HRQoL.

Conclusions: This study showed that OLM/AML/HCTZ reduced blood pressure and significantly increased blood pressure control whilst improving patients' HRQoL. Achieving blood pressure control, amount of concomitant medication and dosage strength of antihypertensive impacted on patients' HRQoL.

Figures

Figure 1
Figure 1
Mean MINICHAL scores per patient at different times from the start of antihypertensive treatment. Not all patients completed all HRQoL instruments at each time point.
Figure 2
Figure 2
Mean EQ-5D scores per patient at different times from the start of antihypertensive treatment. Not all patients completed all HRQoL instruments at each time point.
Figure 3
Figure 3
Percentages of patients reporting problems across each EQ-5D index dimension at baseline and after 54 weeks of treatment. Data was missing from 10% of patients at baseline and 1% of patients at week 54.

References

    1. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J. 2014. ([Epub ahead of print]). Available from: .
    1. Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SCFF. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29(2):179–88. doi: 10.1097/HJH.0b013e328340d76f.
    1. Zygmuntowicz M, Owczarek A, Elibol A, Chudek J. Comorbidities and the quality of life in hypertensive patients. Pol Arch Med Wewnętrznej. 2012;122(7–8):333–40.
    1. Wang R, Zhao Y, He X, Ma X, Yan X, Sun Y, et al. Impact of hypertension on health-related quality of life in a population-based study in Shanghai. China Pub Health. 2009;123:534–9. doi: 10.1016/j.puhe.2009.06.009.
    1. Aydemir O, Ozdemir C, Koroglu E. The impact of co-morbid conditions on the SF-36: A primary-care-based study among hypertensives. Arch Med Res. 2005;36:136–41. doi: 10.1016/j.arcmed.2004.12.009.
    1. Erickson SR, Williams BC, Gruppen LD. Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls. J Hum Hypertens. 2001;15:539–48. doi: 10.1038/sj.jhh.1001236.
    1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC) J Hypertens. 2007;25(6):1105–87. doi: 10.1097/HJH.0b013e3281fc975a.
    1. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of european guidelines on hypertension management: a european society of hypertension task force document. J Hypertens. 2009;27(11):2121–58. doi: 10.1097/HJH.0b013e328333146d.
    1. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252–69. doi: 10.1016/j.clinthera.2010.07.008.
    1. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32(10):1. doi: 10.2165/11636320-000000000-00000.
    1. Volpe M, de la Sierra A, Ammentorp B, Laeis P. Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. Adv Ther. 2014;31(5):561–74. doi: 10.1007/s12325-014-0117-9.
    1. EuroQol. EQ-5D. Available from: .
    1. Badia X, Roca-Cusachs A, Dalfo A, Gascon G, Abellan J, Lahoz R, Varela C, Velasco O. Validation of the short form of the Spanish Hypertension Quality of Life Questionnaire (MINICHAL) Clin Ther. 2002;24(12):2137–54. doi: 10.1016/S0149-2918(02)80103-5.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–108. doi: 10.1097/00005650-199711000-00002.
    1. Roca-cusachs À, Badia X, Dalfó A, Gascón G, De Bienestar Í. Relación entre variables clínicas y terapéuticas y calidad de vida relacionada con la salud en pacientes con hipertensión arterial. Estudio MINICHAL. Med Clin. 2003;121(1):12–7. doi: 10.1016/S0025-7753(03)74112-8.
    1. Schulz RB, Rossignoli P, Correr CJ, Fernández-Llimós FTP. Validation of the short form of the spanish hypertension quality of life questionnaire ( MINICHAL) for Portuguese ( Brazil) Arq Bras Cardiol. 2008;90(2):127–31. doi: 10.1590/S0066-782X2008000200010.
    1. Carvalho MA, Silva IB, Ramos SB, Coelho LF, Goncalves ID, Figueiredo Neto JA, et al. Quality of life of hypertensive patients and comparison of two instruments of HRQOL measure. Arq Bras Cardiol. 2012;98(5):442–50. doi: 10.1590/S0066-782X2012005000032.
    1. Roca-Cusachs A, Dalfó A, Badia X, Arístegui I, Roset M. Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens. 2001;19(10):1913–9. doi: 10.1097/00004872-200110000-00028.
    1. Youssef RM, Moubarak II, Kamel MI. Factors affecting the quality of life of hypertensive patients. East Mediterr Heal J. 2005;11(1–2):109–18.
    1. Santos L, Chaves C, Andrade A, Duarte J. The influence of stress on the quality of life of hypertensive patients. Procedia - Soc Behav Sci Elsevier B V. 2014;113:16–25. doi: 10.1016/j.sbspro.2014.01.006.
    1. Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am Soc Hypertens. 2013;7(1):46–60. doi: 10.1016/j.jash.2012.11.001.
    1. Antihypertensive Pill Burden & Patient Adherence. Available from: .
    1. Zyoud SH, Al-Jabi SW, Sweileh WM, Wildali AH, Saleem HM, Aysa HA, et al. Health-related quality of life associated with treatment adherence in patients with hypertension: a cross-sectional study. Int J Cardiol. 2013;168(3):2981–3. doi: 10.1016/j.ijcard.2013.04.105.
    1. DiMatteo MR, Giordani PJ, Lepper HSCT. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811. doi: 10.1097/00005650-200209000-00009.
    1. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–9. doi: 10.1016/j.ahj.2007.12.011.
    1. Szende A, Janssen B, Cabases J. Self-Reported Population Health: An International Perspective based on EQ-5D. Szende A, Janssen B, Cabases J, editors. Dordrecht: Springer Netherlands; 2014. Available from: .
    1. Whynes DK. Does the correspondence between EQ-5D health state description and VAS score vary by medical condition? Health Qual Life Outcomes. 2013;11:155. doi: 10.1186/1477-7525-11-155.
    1. Maatouk I, Wild B, Herzog W, Wesche D, Schellberg D, Schöttker B, et al. Longitudinal predictors of health-related quality of life in middle-aged and older adults with hypertension: results of a population-based study. J Hypertens. 2012;30(7):1364–72. doi: 10.1097/HJH.0b013e328353d81b.
    1. Huang IC, Frangakis C, Atkinson MJ, Willke RJ, Leite WL, Vogel WB, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res. 2008;43(1 Pt 1):327–39.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅